Has Usah Lilavivat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,197 in general payments to Usah Lilavivat, MD across 602 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Usah Lilavivat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Usah Lilavivat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Usah Lilavivat, MD

Endocrinology, Diabetes & Metabolism · Sumter, SCNPI 1437241262

Payments from drug & device makers

$13,197in general payments, 2019–2025

Across 602 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$2K
Novo Nordisk$2K
Lilly USA, LLC$937
Corcept Therapeutics$792
AstraZeneca$629
Xeris Pharmaceuticals, Inc.$580
plus $6K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	119	$2,491
Novo Nordisk	43	$1,607
Lilly USA, LLC	55	$937
Corcept Therapeutics	48	$792
AstraZeneca(2 entities)	29	$629
Xeris Pharmaceuticals, Inc.	29	$580
Vifor Pharma, Inc.	27	$501
Abbott	22	$486
Insulet Corporation	14	$416
Sanofi-aventis U.S. LLC	19	$378
Boehringer Ingelheim	14	$370
Dexcom, Inc.	8	$310
Merck	16	$302
Otsuka America Pharmaceutical, Inc.	13	$290
Novartis	9	$268
Bayer	15	$237
Mannkind Corporation	10	$233
Mallinckrodt Hospital Products Inc.	8	$154
GSK	7	$144
Takeda Pharmaceuticals U.S.A., Inc.	6	$136
Amarin Pharma, Inc.	8	$135
Daiichi Sankyo Inc.	6	$124
Renalytix AI, Inc.	6	$122
OPKO Pharmaceuticals, LLC	6	$109
Cequr Corporation	3	$104
Valeritas, Inc.	2	$99
Madrigal Pharmaceuticals	1	$91
Tosoh Bioscience, Inc.	1	$91
Calliditas Therapeutics US Inc.	4	$89
Aurinia Pharma U.S., Inc.	3	$77
Shire North American Group Inc	4	$73
Alnylam Pharmaceuticals Inc.	3	$66
Tandem Diabetes Care, Inc.	4	$63
Medtronic(2 entities)	4	$60
Esperion Therapeutics, Inc.	2	$59
Travere Therapeutics, Inc.	3	$57
Pfizer	3	$55
Ascensia Diabetes Care US Inc.	2	$46
Ascendis Pharma Endocrinology Inc	2	$43
Mallinckrodt Enterprises LLC	3	$38
Senseonics, Incorporated	3	$37
Johnson & Johnson	2	$33
BETA Bionics, Inc.	2	$32
Ultragenyx Pharmaceutical Inc.	2	$27
Ardelyx, Inc.	1	$24
Kyowa Kirin, Inc.	1	$23
Zealand Pharma US, Inc.	1	$23
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$18
Radius Health, Inc.	1	$17
Organogenesis Inc.	1	$17
Recordati_rare_diseases_inc.	1	$17
Arbor Pharmaceuticals, Inc.	1	$16
Clarus Therapeutics Inc.	1	$14
Antares Pharma, Inc.	1	$13
Companion Medical, Inc.	1	$13
G Medical Diagnostic Services, Inc.	1	$12

How this compares

$13,197 in reported general payments places this provider in the 70th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024

$474,195

Medicare patients

572

Services billed

12,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Sumter

Ronald MayfieldSpartanburg$8.9M
Donald EagertonMyrtle Beach$7.9M
Beatrice HullCharleston$987K
Anne LarochelleMyrtle Beach$678K
Gauri DhirMyrtle Beach$417K
Cory WhiteGreenville$413K
Louis HaenelCharleston$377K
Vonda CalcuttWalterboro$368K
Kathie HermayerCharleston$337K
Ray VaughtersAiken$321K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →